I am delighted that oncologists finally have a way to identify HR+/HER2- early breast cancer patients who will benefit from anthracycline therapy," said Joyce A. O’Shaughnessy, M.D., principal ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with ...

A scientist in the French city of Orleans holds up a test tube containing messenger RNA While mRNA was discovered in the early 1960s, it rose to global prominence when it was used in some Covid ...

Serum alpha-fetoprotein (AFP) is the current standard of care and only approved biomarker for hepatocellular carcinoma (HCC), used for diagnosis, outcome prediction, long-term follow-up, and treatment ...